Halma's latest acquisitions strengthen its healthcare portfolio in attractive, fast-growing markets, UBS analysts say in a research note. The deals complement the U.K. maker of health and safety equipment's existing businesses by expanding its capabilities in digital hospital management and precision cancer treatment, the analysts say. The acquisitions are expected to provide a modest boost to earnings while creating opportunities for stronger long-term revenue growth through a broader product offering and international expansion, the analysts say. With four deals completed since the start of the fiscal year, UBS remains confident that disciplined bolt-on acquisitions will continue to support the company's long-term growth, they say. Shares trade 0.8% higher at 3,978 pence. (nina.kienle@wsj.com)